11.2 Pharmacotherapy: Bisphosphonates, Denosumab, Anabolic Agents & Patient Education

Pharmacotherapy: Bisphosphonates, Denosumab, Anabolic Agents & Patient Education

Core Clinical Principle: Pharmacologic management of osteoporosis is divided into Antiresorptive Agents (which inhibit osteoclast activity to decrease bone breakdown) and Anabolic Agents (which stimulate osteoblasts to build new bone matrix). The orthopaedic nurse plays a pivotal role in enforcing strict ingestion protocols, managing rare long-term drug risks (AFF and MRONJ), and ensuring seamless transitions to prevent catastrophic rebound fracture cascades.

Effective management of metabolic bone fragility requires tailoring pharmacotherapy to fracture risk severity, renal function, comorbidities, and patient compliance capabilities.

---

1. Antiresorptive Agents: Oral & Intravenous Bisphosphonates

Bisphosphonates are stable synthetic analogues of pyrophosphate that bind avidly to hydroxyapatite crystals on bone surfaces. During osteoclastic bone resorption, internalized bisphosphonates inhibit farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway, disrupting intracellular protein prenylation and inducing rapid osteoclast apoptosis.

                      BISPHOSPHONATE COMPARATIVE PROFILE
  ┌─────────────────────┬───────────────────┬───────────────┬────────────────────────────┐
  │ Medication          │ Route & Frequency │ Bioavailab.   │ Key Nursing Mandates       │
  ├─────────────────────┼───────────────────┼───────────────┼────────────────────────────┤
  │ Alendronate         │ Oral: 70 mg weekly│ <1% absorption│ 8 oz tap water; fasting;   │
  │ (Fosamax)           │ or 10 mg daily    │ (inhibited by │ upright ≥30 min            │
  │                     │                   │ food/calcium) │                            │
  ├─────────────────────┼───────────────────┼───────────────┼────────────────────────────┤
  │ Risedronate         │ Oral: 35 mg weekly│ <1% absorption│ 8 oz tap water; fasting;   │
  │ (Actonel)           │ or 150 mg monthly │               │ upright ≥30 min            │
  ├─────────────────────┼───────────────────┼───────────────┼────────────────────────────┤
  │ Ibandronate         │ Oral: 150 mg/month│ <1% absorption│ 8 oz tap water; fasting;   │
  │ (Boniva)            │ or 3 mg IV q3mo   │               │ upright ≥60 min            │
  ├─────────────────────┼───────────────────┼───────────────┼────────────────────────────┤
  │ Zoledronic Acid     │ IV: 5 mg infusion │ 100% systemic │ Infuse over ≥15 min; hydrate│
  │ (Reclast)           │ once yearly       │ delivery      │ Acetaminophen for APR      │
  └─────────────────────┴───────────────────┴───────────────┴────────────────────────────┘

Oral Bisphosphonate Administration Protocol

Oral bisphosphonates have notoriously poor intestinal bioavailability ($<1%$), and their chemical structure causes severe local mucosal irritation if retained in the upper GI tract.

• Timing: Administer first thing in the morning upon arising from sleep.
• Fluid: Swallow with a full glass (8 ounces / 240 mL) of plain tap water only. Patients must never take bisphosphonates with mineral water, coffee, tea, orange juice, or milk, as divalent cations ($Ca^{2+}, Mg^{2+}, Fe^{2+}$) chelate the drug, reducing absorption to zero.
• Fasting Requirement: Maintain strict fasting (no food, beverages, or other medications) for at least 30 minutes (alendronate, risedronate) or 60 minutes (ibandronate).
• Posture: The patient must remain strictly upright (sitting or standing) for at least 30 minutes (60 minutes for ibandronate). They must never recline or lie down until after they have consumed their first meal of the day.
  • Pathology: Pill entrapment in the esophagus causes severe chemical esophagitis, esophageal ulceration, erosive strictures, and potential perforation.
• Contraindications: Esophageal motility disorders (achalasia, severe strictures), inability to remain upright for 30–60 minutes, uncorrected hypocalcemia, and severe renal insufficiency ($eGFR <35\text{ mL/min}$). ($eGFR <30\text{ mL/min}$ for risedronate/ibandronate).

Intravenous Zoledronic Acid & The Acute Phase Reaction

Zoledronic acid (5 mg IV annually over $\ge 15\text{ minutes}$) bypasses the GI tract entirely, guaranteeing 100% compliance.

• The Acute Phase Reaction (APR): Within 24 to 72 hours following the initial IV infusion, 30% to 40% of drug-naive patients experience a transient, self-limiting flu-like syndrome characterized by fever, chills, myalgias, arthralgias, bone pain, and headache. APR is mediated by the rapid release of pro-inflammatory cytokines (IL-6, TNF-$\alpha$) from circulating $\gamma\delta$ T-cells.
• Nursing Prevention & Management:
  • Ensure adequate pre-hydration (encourage 2 glasses of water prior to infusion).
  • Co-administer prophylactic acetaminophen (500–1,000 mg) or an NSAID immediately prior to infusion and continue every 6 hours for 48–72 hours post-infusion as needed.

---

2. Rare Long-Term Antiresorptive Complications & The Drug Holiday

Because bisphosphonates embed deeply in the mineralized hydroxyapatite lattice and persist in the skeleton for years, long-term profound suppression of bone remodeling can lead to structural micro-damage accumulation.

               ATYPICAL FEMUR FRACTURE (AFF) vs. MRONJ SURVEILLANCE
  ┌─────────────────────┬─────────────────────────────────┬──────────────────────────────┐
  │ Complication        │ Clinical Presentation & Signs   │ Nursing & Medical Actions    │
  ├─────────────────────┼─────────────────────────────────┼──────────────────────────────┤
  │ Atypical Femur      │ • Prodromal dull, aching thigh  │ • Discontinue antiresorptive │
  │ Fracture (AFF)      │   or groin pain for weeks/months│ • Order BILATERAL full-length│
  │                     │ • Low-energy subtrochanteric/   │   femur X-rays (high bilateral)│
  │                     │   diaphyseal location           │ • Non-weight-bearing status  │
  │                     │ • Lateral cortical 'beaking'    │ • Urgent orthopaedic consult │
  │                     │ • Transverse fracture line      │   for prophylactic IM nailing│
  ├─────────────────────┼─────────────────────────────────┼──────────────────────────────┤
  │ Medication-Related  │ • Exposed, necrotic maxilla or  │ • Mandatory pre-treatment    │
  │ Osteonecrosis of    │   mandible bone >8 weeks        │   comprehensive dental exam  │
  │ the Jaw (MRONJ)     │ • Localized pain, soft tissue   │ • Complete invasive oral sx  │
  │                     │   swelling, purulent drainage   │   BEFORE starting drug       │
  │                     │ • Triggered by dental extraction│ • Chlorhexidine rinses; oral │
  │                     │   or periodontal surgery        │   hygiene; conservative care │
  └─────────────────────┴─────────────────────────────────┴──────────────────────────────┘

The "Drug Holiday" Concept

After 3 to 5 years of oral bisphosphonates or 3 years of IV zoledronic acid, patients must be reassessed for fracture risk:

• Moderate-Risk Patients: Discontinuing the drug for a temporary "holiday" of 2 to 3 years allows the skeleton to clear micro-damage and significantly reduces the incidence of AFF and MRONJ, while residual skeletal drug stores maintain BMD and fracture protection.
• High-Risk Patients (T-score $\le -2.5$ at hip, older age, prior fragility fracture): Continue therapy for up to 10 years or switch to an anabolic agent.

---

3. Targeted Antiresorptive: Denosumab (Prolia)

Denosumab is a fully human IgG2 monoclonal antibody that binds with high affinity to RANKL, preventing it from activating the RANK receptor on osteoclasts.

• Dosing & Administration: 60 mg subcutaneous injection administered by a healthcare professional once every 6 months.
• Renal Clearance Profile: Unlike bisphosphonates, denosumab is cleared by the reticuloendothelial system and is not cleared by the kidneys. It can be safely administered to patients with chronic kidney disease (CKD Stages 1–5), though severe hypocalcemia is a major hazard in advanced renal disease; serum calcium must be checked and corrected prior to each injection.

  ┌────────────────────────────────────────────────────────────────────────────┐
  │     CRITICAL CLINICAL WARNING: DENOSUMAB REBOUND FRACTURE CASCADE          │
  ├────────────────────────────────────────────────────────────────────────────┤
  │ Unlike bisphosphonates, denosumab DOES NOT embed into bone matrix. When    │
  │ the 6-month dose wears off, its antiresorptive effect ceases rapidly.      │
  │ Delayed or missed dosing causes a rapid REBOUND SURGE in osteoclast activity│
  │ and bone resorption markers, peaking within 9 to 12 months after the last  │
  │ injection. This causes rapid bone density loss and an alarming cluster of  │
  │ MULTIPLE VERTEBRAL COMPRESSION FRACTURES (Rebound Vertebral Fractures).     │
  │                                                                            │
  │ MANDATORY NURSING ACTION: Teach patients NEVER to skip, delay, or stop     │
  │ denosumab. If denosumab must be discontinued, the patient MUST immediately │
  │ be transitioned to an alternate antiresorptive (e.g., IV zoledronic acid   │
  │ given 6 months post-last Prolia injection) to "lock in" bone gains.        │
  └────────────────────────────────────────────────────────────────────────────┘

---

4. Anabolic (Bone-Forming) & Dual-Action Agents

                     ANABOLIC & DUAL-ACTION PHARMACOTHERAPY
  ┌─────────────────────┬───────────────────┬───────────────┬────────────────────────────┐
  │ Agent & Class       │ Dosing Regimen    │ Mechanism     │ Clinical Directives        │
  ├─────────────────────┼───────────────────┼───────────────┼────────────────────────────┤
  │ Teriparatide        │ 20 mcg SubQ daily │ Recombinant   │ Max 2-year lifetime limit; │
  │ (Forteo)            │ prefilled pen     │ human PTH     │ Administer seated (syncope)│
  │ [PTH 1-34 Analogue] │                   │ (1-34)        │ Monitor hypercalcemia      │
  ├─────────────────────┼───────────────────┼───────────────┼────────────────────────────┤
  │ Abaloparatide       │ 80 mcg SubQ daily │ Synthetic     │ Max 2-year lifetime limit; │
  │ (Tymlos)            │ prefilled pen     │ PTHrP analogue│ Refrigerate pen before use;│
  │ [PTHrP Analogue]    │                   │               │ Lower hypercalcemia risk   │
  ├─────────────────────┼───────────────────┼───────────────┼────────────────────────────┤
  │ Romosozumab         │ 210 mg SubQ monthly│ Sclerostin    │ Exactly 12-month course;   │
  │ (Evenity)           │ (2 x 105 mg SubQ  │ monoclonal    │ Boxed Warning: Avoid if MI │
  │ [Dual-Action]       │ injections)       │ antibody      │ or stroke within past 1 yr │
  └─────────────────────┴───────────────────┴───────────────┴────────────────────────────┘

Teriparatide & Abaloparatide (PTH/PTHrP Analogues)

• Anabolic Mechanism: Continuous elevation of parathyroid hormone (as in hyperparathyroidism) catabolizes bone. However, intermittent, once-daily pulsatile administration preferentially stimulates osteoblast differentiation and lifespan over osteoclast resorption, generating a true "anabolic window" of new trabecular bone formation.
• Lifetime Duration: Strictly limited to a maximum of 2 years (24 months) cumulative lifetime exposure across all PTH analogues due to historical rodent studies showing osteosarcoma risk.
• Contraindications: Paget's disease of bone, unexplained elevated alkaline phosphatase, prior skeletal radiation therapy, bone metastases, primary hyperparathyroidism, or pre-existing hypercalcemia.
• Nursing Directives: Administer the initial doses while the patient is seated or lying down to prevent falls from transient orthostatic hypotension.

Romosozumab (Evenity: Sclerostin Inhibitor)

• Dual-Action Mechanism: Sclerostin is an osteocyte-secreted glycoprotein that halts bone formation by blocking the Wnt/$\beta$-catenin pathway. Romosozumab binds and neutralizes sclerostin, which produces a dramatic, simultaneous increase in bone formation and decrease in bone resorption.
• Duration: Administered as two consecutive subcutaneous injections (210 mg total) once monthly for exactly 12 months. After 12 months, the anabolic effect wanes, and the patient MUST transition to an antiresorptive (e.g., alendronate or zoledronic acid) to maintain newly formed bone.
• Black Box Cardiovascular Warning: Romosozumab is associated with an increased risk of myocardial infarction, stroke, and cardiovascular death. It is strictly contraindicated in patients who have experienced a myocardial infarction or stroke within the preceding 12 months.

---

5. Nutritional Supplementation & Patient Education

                      CALCIUM & VITAMIN D SUPPLEMENTATION
  ┌─────────────────────┬──────────────────────────┬────────────────────────────┐
  │ Parameter           │ Calcium                  │ Vitamin D3 (Cholecalciferol)│
  ├─────────────────────┼──────────────────────────┼────────────────────────────┤
  │ Daily Target        │ • 1,000 mg/d (Men 50–70) │ • 800 – 2,000 IU/day       │
  │                     │ • 1,200 mg/d (Women ≥51, │ • Target serum 25(OH)D:    │
  │                     │   Men ≥71) (Diet + Supp) │   ≥30 ng/mL (75 nmol/L)    │
  ├─────────────────────┼──────────────────────────┼────────────────────────────┤
  │ Formulation Types   │ • Carbonate (40% Ca):    │ • D3 (cholecalciferol) is  │
  │                     │   Take WITH food; acid-dep.│  superior to D2 in raising │
  │                     │ • Citrate (21% Ca):      │  and maintaining serum     │
  │                     │   Take w/ or w/o food;   │  25-OH-D levels            │
  │                     │   Ideal for PPI / Elderly│                            │
  ├─────────────────────┼──────────────────────────┼────────────────────────────┤
  │ Dosing Principle    │ Max 500 – 600 mg         │ Fat-soluble; take with a   │
  │                     │ elemental Ca per single  │ meal containing healthy    │
  │                     │ dose (saturable transport│ dietary fats               │
  └─────────────────────┴──────────────────────────┴────────────────────────────┘